DC DEZAWA CELL INNOVATIONS.
LIVE

Serial Number

99859270

Owner

MUSECELL INNOVATIONS PTE. LTD.

Attorney

Betsy Wang Lee

Filing Date

Jun 2, 2026

Add to watchlist:

No watchlists yet
View on USPTO

DC DEZAWA CELL INNOVATIONS. Trademark

Serial Number: 99859270

DC DEZAWA CELL INNOVATIONS. is a trademark filed by MUSECELL INNOVATIONS PTE. LTD. on June 2, 2026. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

MUSECELL INNOVATIONS PTE. LTD. (50 trademarks)

20 COLLYER QUAY,

Entity Type: 24

Trademark Details

Filing Date

June 2, 2026

Registration Date

Not Registered

Goods & Services

Cells for medical purposes; Cells for medical use; Cellular function activating agents for medical purposes; Cellulose esters for pharmaceutical purposes; Cellulose ethers for pharmaceutical purposes; Cellulose for pharmaceutical purposes; Chemicals for cell separation and cultivation for medical or veterinary purposes; Chemicals for separating and cultivating cells for medical or veterinary purposes; Living cells for medical purposes; Living cells for medical use; Pharmaceutical compositions containing stem cells for the treatment of diseases; Pharmaceutical preparations containing stem cells; Pharmaceutical preparations for activating cellular function; Stem cells for medical purposes; Autoinjectors prefilled with pharmaceutical preparations; Immunological products for intravenous injections; Injectable medicinal solutions; Injectable solutions for medical purposes; Injectable solutions for use in inhibiting peristalsis for medical purposes; Pharmaceutical preparations sold in pre-filled injectors; Intravenous fluids used for the delivery of pharmaceutical preparations; Intravenous solutions for medical purposes; Immunosuppressive pharmaceutical preparations; Pharmaceutical preparations for the treatment of cystic fibrosis; Glycerophosphates; Phosphates for pharmaceutical purposes; Cardiovascular agents for medical purposes; Cardiovascular pharmaceutical preparations; Cardiovascular pharmaceuticals; Cardiovascular preparations; Cardiovascular treatment preparations; Drugs for the treatment of cardiovascular diseases; Medicines for the treatment of cardiovascular and cerebrovascular diseases; Pharmaceutical preparations and substances for the prevention of cardiovascular diseases and disorders; Pharmaceutical preparations and substances for the treatment of cardiovascular diseases and disorders; Pharmaceutical preparations for the prevention of cardiovascular disorders; Pharmaceutical preparations for the treatment of cardiovascular disease; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for the treatment of cardiovascular disorders; Pharmaceutical preparations for treating cardiovascular diseases; Pharmaceutical preparations for the prevention and treatment of kidney diseases; Anti-ulcer agents; Pharmaceutical preparations being antiulceratives; Pharmaceutical preparations for the treatment of chronic liver diseases; Pharmaceutical preparations for the treatment of neurovascular ischemic conditions and for post-ischemic recovery

Filing History

APPLICATION FILING RECEIPT MAILED
Jun 2, 2026 MAFR
NEW APPLICATION ENTERED
Jun 2, 2026 NWAP